ATE292981T1 - Tat transdominante variante aus human immunodeficiency virus - Google Patents

Tat transdominante variante aus human immunodeficiency virus

Info

Publication number
ATE292981T1
ATE292981T1 AT94400005T AT94400005T ATE292981T1 AT E292981 T1 ATE292981 T1 AT E292981T1 AT 94400005 T AT94400005 T AT 94400005T AT 94400005 T AT94400005 T AT 94400005T AT E292981 T1 ATE292981 T1 AT E292981T1
Authority
AT
Austria
Prior art keywords
act
immunodeficiency virus
human immunodeficiency
variant
contg
Prior art date
Application number
AT94400005T
Other languages
English (en)
Inventor
Majid Mehtali
Tania Sorg
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Application granted granted Critical
Publication of ATE292981T1 publication Critical patent/ATE292981T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT94400005T 1993-01-04 1994-01-03 Tat transdominante variante aus human immunodeficiency virus ATE292981T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9300004A FR2700169B1 (fr) 1993-01-04 1993-01-04 Nouveaux variants trans-dominants TAT du virus de l'immunodéficience humaine.

Publications (1)

Publication Number Publication Date
ATE292981T1 true ATE292981T1 (de) 2005-04-15

Family

ID=9442808

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94400005T ATE292981T1 (de) 1993-01-04 1994-01-03 Tat transdominante variante aus human immunodeficiency virus

Country Status (10)

Country Link
US (2) US5889175A (de)
EP (3) EP1424394A3 (de)
JP (2) JP3613734B2 (de)
AT (1) ATE292981T1 (de)
AU (1) AU668441B2 (de)
CA (1) CA2112652A1 (de)
DE (1) DE69434328T2 (de)
DK (1) DK0614980T3 (de)
ES (1) ES2236688T3 (de)
FR (1) FR2700169B1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2215483C (fr) * 1995-03-08 2012-01-03 Jean-Francois Zagury Immunogenes denues de toxicite derivant d'une proteine de regulation retrovirale, anticorps, procede de preparation et compositions pharmaceutiques les renfermant
FR2731355B1 (fr) * 1995-03-08 1997-05-30 Neovacs Nouveaux immunogenes, nouveaux anticorps, procede de preparation et compositions pharmaceutiques les renfermant
US5888767A (en) 1996-11-27 1999-03-30 The Johns Hopkins University School Of Medicine Method of using a conditionally replicating viral vector to express a gene
US5885806A (en) * 1995-11-28 1999-03-23 The Johns Hopkins University School Of Medicine Methods to prepare conditionally replicating viral vectors
RO118887B1 (ro) * 1996-01-29 2003-12-30 Virologic, Inc. Metodă pentru determinarea sensibilităţii sau eficacităţii biologice şi rezistenţei omului la medicamentele antivirale
US6686333B1 (en) * 1996-10-04 2004-02-03 The United States Of America As Represented By The Department Of Health And Human Resources Inhibition of HIV replication using soluble Tat peptide analogs
WO1998014587A1 (en) * 1996-10-04 1998-04-09 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTEMENT OF HEAL TH AND HUMAN SERVICES Inhibition of hiv replication using soluble tat peptide analogs
US5891994A (en) * 1997-07-11 1999-04-06 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
FR2792206B1 (fr) * 1999-04-13 2006-08-04 Centre Nat Rech Scient Vaccin anti-vih-1 comprenant tout ou partie de la proteine tat de vih-1
FR2792204B1 (fr) * 1999-04-13 2001-07-13 Centre Nat Rech Scient Vaccin anti-vih-1 comprenant tout en partie de la proteine tat de vih-1
US8323928B2 (en) 1999-08-12 2012-12-04 Pin Pharma, Inc. Vaccines and immunotherapeutics derived from the human immunodeficiency virus (HIV) transactivator of transcription protein for the treatment and prevention of HIV disease
US20050226890A1 (en) * 1999-08-12 2005-10-13 Cohen David I Tat-based vaccine compositions and methods of making and using same
CA2398269C (en) * 1999-08-12 2013-04-09 David I. Cohen Non-immunosuppressant hiv tat
US6399067B1 (en) * 2000-04-28 2002-06-04 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
US20080044435A1 (en) * 2004-03-16 2008-02-21 Cohen David I Tat-Based Tolerogen Compositions and Methods of Making and Using Same
US6946267B2 (en) * 2002-03-13 2005-09-20 Dr. Chip Biotechnology Inc. Method for detecting Staphylococcus aureus
US20050208482A1 (en) * 2004-03-16 2005-09-22 Cohen David I Tat-based immunomodulatory compositions and methods for their discovery and use
WO2006088740A2 (en) 2005-02-15 2006-08-24 Thymon, L.L.C. Methods and compositions for impairing multiplication of hiv-1
BRPI1009215B1 (pt) 2009-03-23 2019-10-29 Nanirx Inc composição farmacêutica compreendendo uma sequência de aminoácidos modificada da proteína trans-ativadora de transcrição (tat) do vírus da imunodeficiência humana (hiv) e uso de um polipeptídeo derivado de tat para tratar câncer
IT1397569B1 (it) 2009-12-10 2013-01-16 Icgeb Peptidi e loro derivati che inibiscono il rilascio extracellulare della proteina tat di hiv-1 e la replicazione di hiv-1.
FR2982277B1 (fr) 2011-11-08 2015-08-21 Agronomique Inst Nat Rech Cassette d'expression inductible et ses utilisations
US9663556B2 (en) 2013-10-04 2017-05-30 Pin Pharma, Inc. Treatment of cancers with immunostimulatory HIV tat derivative polypeptides

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3756789A (en) * 1988-06-16 1990-01-12 St. Louis University Antagonists of viral transactivating proteins

Also Published As

Publication number Publication date
EP1424394A3 (de) 2005-10-05
AU5280393A (en) 1994-07-14
FR2700169B1 (fr) 1995-03-24
EP1580272A2 (de) 2005-09-28
US6284252B1 (en) 2001-09-04
JP3613734B2 (ja) 2005-01-26
CA2112652A1 (fr) 1994-07-05
JPH06234791A (ja) 1994-08-23
ES2236688T3 (es) 2005-07-16
EP1424394A2 (de) 2004-06-02
EP0614980A1 (de) 1994-09-14
FR2700169A1 (fr) 1994-07-08
JP2004065256A (ja) 2004-03-04
DE69434328D1 (de) 2005-05-19
AU668441B2 (en) 1996-05-02
EP0614980B1 (de) 2005-04-13
DE69434328T2 (de) 2006-03-09
EP1580272A3 (de) 2005-10-05
DK0614980T3 (da) 2005-08-08
US5889175A (en) 1999-03-30

Similar Documents

Publication Publication Date Title
ATE292981T1 (de) Tat transdominante variante aus human immunodeficiency virus
ATE173478T1 (de) Varianten des pankreatischen rinder- trypsininhibitors, deren herstellung und verwendung
EP0728764A4 (de) Peptide das eine immunantwort gegen hiv unduziert und arzneimittel die esenthaelt zur vorbeugung oder behandlung von aids
TR199501134A2 (tr) Memeli ve viral proteinleri asiri ifade edilmesi.
NO20100324L (no) Fremgangsmate for trinnvis festing av polyetylenglykol (PEG) andeler i serie til et polypeptid
AR009436A1 (es) UNA PROTEíNA DE FUSIoN FC-OB, UNA SECUENCIA DE ÁCIDO NUCLEICO QUE LA CODIFICA, UN VECTOR, PROCEDIMIENTO DE PREPARACIoN, COMPOSICIONES FARMACÉUTICAS Y USOS.
EP0370458A3 (de) Von synthetischer DNS abgeleitete rekombinante HIV-1-Antigene
DE3770915D1 (de) Menschliches apolipoprotein a1 sowie dessen variante, exprimiert in escherichia coli.
GR852940B (de)
NO910982L (no) Uratoksydase-aktivt protein, rekombinant gen som koder for det, ekspresjonsvektor, mikroorganismer og transformerteceller.
EP1380648A3 (de) Rekombinante DNAse B aus Streptococcus pyogenes
DE3881023D1 (de) Proteine, expressionsvektoren, die fuer solche proteine kodierende dna enthalten und zellen, die solche expressionsvektoren enthalten.
DK0728208T3 (da) Tomat-xyloglucan-endo-transglycosylase
FR2732346B1 (fr) Proteines mutees, codees par un gene env mute de lentivirus, fragments peptidiques inclus dans lesdites proteines, vecteurs d'expression exprimant lesdites proteines mutees et leurs applications
CA2032167A1 (en) Dna coding for protein binds to enhancer of.alpha.-fetoprotein gene
EP1251176A3 (de) Expressionssysteme, die selbstspaltende Fusionsproteine verwenden sowie ein reduzierendes Polypeptid
DE69333304D1 (de) Erhöhte produktion von sekretierten proteinen durch rekombinante eukaryotische zellen
ATE216706T1 (de) Peptide des hiv-gag proteins, ihre herstellung und verwendung
CA2163805A1 (en) Novel activating factor of leukocytes
CA2134080A1 (en) Natural humain igm antibodies
AU637589B2 (en) Ancrod proteins, their production and use
FI962047A0 (fi) Endoteliiniä muuntava entsyymi
CA2067334A1 (en) Recombinant production of lactoperoxidase
KR920700224A (ko) 신규의 생리활성 펩티드 및 이를 유효성분으로서 함유한 칼슘대사 조절제
AU1275095A (en) Antiviral composition of viral protein trans-dominant variants

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0614980

Country of ref document: EP

REN Ceased due to non-payment of the annual fee